Brief: Arch Biopartners Announces FDA Acknowledgement Of Investigational New Drug Application For Metablok
15/06/2020 13:27
June 15 (Reuters) - Arch Biopartners Inc ARCH.V :
* ARCH BIOPARTNERS ANNOUNCES FDA ACKNOWLEDGEMENT OF ITS
INVESTIGATIONAL NEW DRUG APPLICATION FOR METABLOK (LSALT
PEPTIDE)
* ARCH BIOPARTNERS - FDA ACKNOWLEDGEMENT ENABLES CO TO
INITIATE
PHASE II TRIAL IN U.S. TO PREVENT LUNG, KIDNEY ORGAN INJURY IN
COVID-19 PATIENTS
* ARCH BIOPARTNERS - EXPECTS TO BEGIN PHASE II TRIAL TO
PREVENT
ACUTE LUNG, KIDNEY ORGAN IN COVID-19 PATIENTS BEFORE END OF
SUMMER, 2020
* ARCH BIOPARTNERS INC - PRIMARY ENDPOINT OF PHASE II TRIAL
WAS
EXPANDED TO A COMPOSITE THAT INCLUDES PREVENTION OF ARDS AND AKI
Source text for Eikon: ID:nGNX1LPl91
Further company coverage: ARCH.V
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide